No, the COMPASS Trial Evaluated Rivaroxaban, Not Apixaban
The COMPASS trial specifically tested rivaroxaban (a factor Xa inhibitor) in combination with aspirin versus aspirin alone in patients with stable atherosclerotic vascular disease—apixaban was not studied in this trial. 1
What the COMPASS Trial Actually Studied
The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial randomized 27,395 patients with coronary artery disease (CAD) or peripheral artery disease (PAD) to three treatment arms 1:
- Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily (the dual anti-thrombotic pathway inhibition or DAPI regimen)
- Rivaroxaban 5 mg twice daily alone
- Aspirin 100 mg daily alone
The trial was stopped early for efficacy at a median follow-up of 23 months 1.
Key Efficacy Results with Rivaroxaban
The combination of rivaroxaban 2.5 mg twice daily plus aspirin demonstrated superior outcomes compared to aspirin alone 1, 2:
- 24% reduction in the primary major adverse cardiovascular event (MACE) outcome (cardiovascular death, stroke, or myocardial infarction) 1
- 18% reduction in all-cause mortality 1
- 42% reduction in stroke incidence 1
- 20% net clinical benefit when efficacy and safety were analyzed together 1
The rivaroxaban-alone arm (5 mg twice daily) showed no significant benefit compared to aspirin alone 1.
Why Apixaban Is Not Interchangeable
Apixaban has no FDA indication or evidence base for reducing cardiovascular events in combination with aspirin in stable atherosclerotic disease 3. The evidence supporting dual anti-thrombotic pathway inhibition is specific to rivaroxaban at the 2.5 mg twice-daily dose combined with aspirin 1.
Critical Distinction in Factor Xa Inhibitors
While both rivaroxaban and apixaban are factor Xa inhibitors, they differ in:
- Dosing regimens tested in cardiovascular disease
- Clinical trial evidence supporting their use
- Regulatory approvals for specific indications
When rivaroxaban is contraindicated in patients with PAD or CAD, the recommended alternative is aspirin plus clopidogrel for 1–6 months, then transition to single antiplatelet therapy—not substitution with apixaban 3, 4.
Current Guideline Recommendations for Rivaroxaban
The 2024 ACC/AHA Peripheral Artery Disease Guidelines provide a Class I (strong) recommendation for rivaroxaban 2.5 mg twice daily plus aspirin 75–100 mg daily in 3, 5:
- Patients with symptomatic PAD to reduce MACE and major adverse limb events
- Patients after lower-extremity revascularization (initiated within 10 days of the procedure)
The European Society of Cardiology similarly recommends this rivaroxaban-aspirin combination for high ischemic risk patients without high bleeding risk 3.
Common Pitfall to Avoid
Do not assume that all factor Xa inhibitors are equivalent or interchangeable for cardiovascular risk reduction. The COMPASS trial evidence is specific to low-dose rivaroxaban (2.5 mg twice daily) combined with aspirin 1. Substituting apixaban, edoxaban, or other anticoagulants lacks supporting evidence and regulatory approval for this indication 3.